The Sky Shop For Hope
Women's Fleece Sweatpants (Maroon - Embroidered Ribbon)
Women's Fleece Sweatpants (Maroon - Embroidered Ribbon)
Couldn't load pickup availability
Beyond their comfort, these sweatpants support a meaningful mission. 40% of all revenue from the Everyday Support Fleece Sweatpants goes to Sky Foundation, a non-profit that funds pancreatic cancer research, allowing you to make a difference with every wear.
- 100% cotton face; 65% cotton, 35% polyester blend (Charcoal Heather: 55% cotton, 45% polyester)
- Tightly knit 3-end fleece with 5-thread stitching for durability
- Ribbed waist, cuffs, and gusset at the crotch
- Elastic waistband with flat, color-matched drawstrings
- Two front cross pockets and one back patch pocket
Note: Cozy up in style and show support for pancreatic cancer research with these fleece-lined sweatpants.
Size guide
WAIST (inches) | INSEAM LENGTH (inches) | |
XS | 28 | 28 |
S | 30 | 29 |
M | 32 | 30 |
L | 34 | 31 |
XL | 36 | 32 |
2XL | 38 | 33 |
Share







Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...